Moleculin Biotech Enters into Waiver and Consent Agreement with Investor

Moleculin Biotech, Inc. (NASDAQ: MBRX) recently announced entering into a waiver and consent agreement with an investor from its offering completed on August 19, 2024. The agreement, termed as the “Waiver,” involves the waiver of certain restrictions related to the company’s ability to enter into a “Variable Rate Transaction.”

Under the terms of the Waiver, Moleculin Biotech agreed to several key points. Firstly, the company agreed to reduce the exercise price of specific warrants held by investors, allowing them to purchase an aggregate of 5,828,570 shares of common stock. The exercise price was aligned with the Series C Warrants that may be issued as part of an offering proposed in the Form S-1 registration statement (file number 333-283820).

Additionally, the company agreed to amend the warrants to include specific sections from the Series C Warrants, modify the initial exercise date to coincide with the date the company receives stockholder approval tied to the Series C Warrants, and provide the investor with a cash fee of $750,000 at the closing of the proposed offering.

The filing indicated that Moleculin Biotech’s Chief Financial Officer, Jonathan P. Foster, signed the report on behalf of the company on February 10, 2025, in compliance with the Securities and Exchange Act of 1934.

Investors and stakeholders are encouraged to review the full details of the waiver and consent agreement filed with the Securities and Exchange Commission for a comprehensive understanding of the arrangement between Moleculin Biotech and the investor involved.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Moleculin Biotech’s 8K filing here.

Moleculin Biotech Company Profile

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.